Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

Semaglutide helped people with peripheral artery disease walk further in a large randomized trial, but it is not approved in the US for that use. In STRIDE, people with type 2 diabetes whose legs hurt when they walked managed 13% more treadmill distance after a year on Ozempic 1 mg than those given a placebo.^[1] Novo Nordisk asked the FDA in 2025 to add this to the Ozempic label; the label posted in June 2026 still lists no PAD indication.^[2][3] Many people with PAD can still be prescribed semaglutide under an existing indication.

Peripheral artery disease in brief

Peripheral artery disease is narrowing of the arteries to the legs by the same fatty build-up, atherosclerosis, that causes heart attacks.^[1] The typical symptom is claudication, a cramping ache in the leg muscles that walking brings on and a few minutes of standing still relieves. The guideline notes that PAD, even without symptoms, comes with a higher risk of major cardiovascular events and death, which is why treatment has two aims: protecting the heart and brain, and improving how far the person can walk.^[5]

What STRIDE showed, in one paragraph

STRIDE randomized 792 people with type 2 diabetes and claudication who could still walk more than 200 meters to weekly semaglutide 1.0 mg or a dummy injection for 52 weeks. Treadmill distance before pain forced a stop improved 13% more on semaglutide, and pain-free walking distance 11% more.^[1][2] The size of the benefit held up whether or not people had obesity, whatever their blood-sugar control, and in both sexes.^[6][7] It was a Novo Nordisk trial with a functional end point, a year long, and it did not measure amputations or survival.

The people in STRIDE had a median age of 68, three in four were men, and all had confirmed narrowing on an ankle or toe pressure test (an ankle-brachial index of 0.90 or less, or a toe-brachial index of 0.70 or less).^[1] Their median BMI was 28.7, so many did not have obesity, and the walking benefit did not depend on BMI.^[6] Only people with the mildest symptomatic stage (Fontaine IIa, able to walk more than 200 meters) were enrolled, so the results say nothing about more advanced disease.^[1]

Is semaglutide FDA-approved for PAD?

No. Ozempic’s US prescribing information lists three uses: blood-sugar control in type 2 diabetes, reducing major cardiovascular events in type 2 diabetes with established cardiovascular disease, and slowing kidney decline when diabetes comes with chronic kidney disease.^[3] Its clinical studies section does not include STRIDE. In March 2025 Novo Nordisk said it had submitted a label extension to the FDA based on STRIDE and expected a decision that year (company-reported).^[2] As of the label posted on DailyMed in June 2026, no PAD use has been added.^[3]

In practice the missing indication matters less than it sounds, because PAD already counts as established cardiovascular disease on two labels:

What neither indication promises is better walking. STRIDE used the 1 mg diabetes dose in people with diabetes, and its authors list PAD without diabetes as a question still to be studied.^[1] Whether Wegovy’s higher weight-loss doses improve claudication in people without diabetes is unknown. The SELECT trial page and the SUSTAIN-6 trial page cover the two cardiovascular trials behind those indications.

How it fits with the treatments guidelines recommend

The 2024 ACC/AHA guideline on leg artery disease gives its strongest grade to supervised exercise therapy for people with symptoms, and says supervised exercise or a structured community program should be offered as an initial treatment.^[5] It gives the same grade to cilostazol for improving leg symptoms and walking distance, with the warning that cilostazol must not be used in heart failure of any severity.^[5]

The guideline, written before STRIDE reported, already recommends GLP-1 drugs (liraglutide and semaglutide) or SGLT-2 inhibitors for people with PAD and type 2 diabetes, but to reduce heart attacks and strokes rather than to improve walking.^[5] STRIDE adds a walking benefit to a drug many people with PAD and diabetes would already be offered. It was compared with placebo, not with exercise therapy, so it gives no basis for choosing semaglutide instead of a walking program.

Amputation and limb outcomes

This is where the evidence is thinnest. A 2026 meta-analysis found that in two randomized trials with 3,592 participants, GLP-1 drugs did not significantly change the rate of major limb events or amputation.^[8] Four patient-record studies did link GLP-1 use to about half the amputation risk, but with very low certainty, because people prescribed a newer drug differ in many ways from those who are not.^[8] For people with diabetic foot ulcers, the evidence on blood flow and healing is covered in GLP-1 drugs, foot ulcers and perfusion.

Coverage

Because PAD is not a labeled use, a plan is unlikely to approve semaglutide for claudication alone. A prescription for type 2 diabetes is the usual route for Ozempic, and for Wegovy the cardiovascular indication. Employer plans choose whether to cover weight-loss drugs, and the member’s own plan documents decide. Under Medicare’s GLP-1 Bridge, symptomatic peripheral artery disease with a BMI of 27 or higher qualifies for a $50 monthly copay, though people with type 2 diabetes are left out of the Bridge, since diabetes coverage for these drugs runs through ordinary Part D.^[9] Brand and dose details are on the Ozempic and Wegovy drug pages.

Semaglutide also lowers blood pressure and blood sugar, both of which matter for arteries; those effects are covered in GLP-1 drugs and blood pressure and GLP-1 drugs and insulin resistance.